Tonix Pharmaceuticals Holding Corp. (TNXP)

Second Quarter Saw Progress In Several Therapeutic Areas


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
August 9, 2022
Report ID: 25098
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

Ticker
TNXP
Current Price
$1.23 4.24%
Market Cap
$70.8M
Price Target
Refer to Report
Volume
2.3M
52wk Range
$0.289 - $11.52

Comments

0
No comments yet...
Related Research Reports
12/13/2022

New Antibodies For Treatment and Prevention of COVID-19 Inlicensed
New Antibodies For Treatment and Prevention of COVID-19 Inlicensed (TNXP)
11/8/2022

3Q22 Reported and Clinical Milestones Reiterated
3Q22 Reported and Clinical Milestones Reiterated (TNXP)
9/23/2022

Retrospective Patient Analysis Shows Overlapping Symptoms Of Long COVID and Fibromyalgia
Retrospective Patient Analysis Shows Overlapping Symptoms Of Long COVID and Fibromyalgia (TNXP)
8/9/2022

Second Quarter Saw Progress In Several Therapeutic Areas
Second Quarter Saw Progress In Several Therapeutic Areas (TNXP)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.